Purpose: The principal aim is to review recent data concerning the very long-term outcome of schizophrenia and schizophrenia spectrum disorders. We examine factors that influence outcome, including therapeutic interventions.
| INTRODUC TI ON
There is considerable amount of information about the course of schizophrenia during the first 2 years after the first episode. Most patients respond to antipsychotic treatment, and if that is discontinued or decreased, they are more likely to relapse. [1] [2] [3] [4] However, there is a lack of knowledge about the very long-term effects of antipsychotics. 5 What happens to patients after the first 2 years? Older retrospective studies have addressed this question. 6, 7 The most interesting among them is the Vermont study which found that 68% of chronically and severely ill schizophrenia patients who had not responded sufficiently to chlorpromazine and then participated in a comprehensive rehabilitation programme had no positive or negative symptoms and functioned reasonably well 32 years later. 8 This result was not consistent with the pessimistic view of schizophrenia outcome prevalent at that time. Other studies using much shorter follow-up periods have identified much smaller proportions of schizophrenia patients showing good outcomes.
9,10
Long-term outcome of schizophrenia has been recently receiving increasing attention in the practical context of uncertainties regarding maintenance treatment. Among 14 guidelines and algorithms for maintenance treatment of schizophrenia in general, none recommended discontinuation within 5 years. 11 For the first episode of schizophrenia, 6 of the guidelines recommended discontinuation after the first 1 or 2 years of treatment in certain types of patients.
The discontinuation strategies appear to be controversial, particularly with respect to atypical antipsychotics. 11 It appears that there are no clear guidelines for maintenance treatment of schizophrenia after the first 5 years. Uncertainty regarding the treatment and outcome of schizophrenia and related psychoses beyond 5 years was demonstrated by recent reviews. [12] [13] [14] It is not clear if maintenance
antipsychotic treatment of schizophrenia patients should be continued indefinitely. If long-term treatment can be discontinued in some patients, we do not know how to identify them in advance.
The principal purpose of this review is to examine recent evidence that may contribute to filling these knowledge gaps. We focus on the literature published in the past 10 years. Older studies are reviewed elsewhere.
5,15,16

| ME THOD
The search was conducted between 1 August and 1 November 2017.
It used the string Schizophrenia AND long-term outcome and was 
| RE SULTS
| Description of selected outcome studies
The following text is organised to accompany 17, 18 all studies included in this table describe follow-ups after firstepisode psychosis (FEP). The follow-up duration ranged between 5 and 20 years.
An Irish study 19 was designed to find out whether the course of non-affective psychoses stabilises after an early period of deterioration, and whether duration of untreated psychosis (DUP) correlates with outcome at 8 years after the start of the first episode.
Furthermore, the study explored the effect of the duration of untreated illness (DUI) on the course and outcome. DUP was the period between the onset of the first psychotic symptom and the start of antipsychotic treatment. DUI was the sum of the duration of prodrome and DUP.
The results showed that negative and disorganised symptoms improved between 4 and 8 years. Symptomatic remission and improvement of social functioning were correlated with shorter DUP.
DUI predicted functional improvement between 4 and 8 years of the study. The cohort as a whole appeared to stabilise after 4 years in terms of symptoms and functioning. However, after 4 years, a quality of life scale showed an improvement in subjects with short DUI (DUI ≤ 2 years), but a deterioration in those with DUI > 2 years.
More detailed analyses of the DUP and outcome in an enlarged sample and extended follow-up period were published later by this group 20 and we review that in a subsequent section on predictors of outcome.
Among the studies listed in Table 1, that of Harrow et al   17 recently attracted attention. That study, conducted in the US, prospectively followed 70 schizophrenia patients (diagnosed with DSM-III) for 20 years. 17 There were multiple follow-up time points.
At each time point, Strauss and Carpenter Scale 21 was used to evaluate work functioning, and psychotic symptoms were assessed with another scale. 22 The results indicated that after 4 years, over 70% In a 10-year follow-up study, Hegelstad et al investigated the differences in symptoms and recovery between regional healthcare organisations with and without a comprehensive programme for the early detection of psychosis in Norway and Denmark. 23 The early detection programme combined information campaigns about psychosis with easy access to mental healthcare.
Of 365 eligible patients, 281 (77%) participated in the follow-up study. Although symptomatic remission rates were evenly distributed between groups with and without the early detection programme, a significantly higher percentage of early detection patients had functionally recovered at the 10-year follow-up relative to usual detection patients (30.7% compared with 15.1%, odds ratio = 2.5, 95% CI = 1.2-5.4, P = .017). The difference in functional recovery rates was largely due to a significantly larger proportion of patients in the early detection area who had full-time employment (27.7% compared with 11.0%).
Another study of outcome of schizophrenia in patients who participated in a special early detection and treatment programme was conducted in Australia by Henry et al. 24 The study had a total of 723 participants at baseline, and information was obtained on up to 90% of this cohort. A total of 483 patients from this cohort were diagnosed with schizophrenia spectrum or schizo-affective disorder; the others had affective or other psychoses. As seen in our Table 1, we have limited the present review to the 483 schizophrenia-related patients. In this group, BPRS data at follow-up were available in 317 patients and SANS data in 301 patients. Symptomatic remission at 10-year follow-up was observed at rates exceeding 50%. The authors suggest that this unusual high rate of remission could be due to effects of their early detection and treatment programme, but there was no control group.
It should be noted that while over 50% patients met the remission criteria, the mean BPRS total scores at follow-up for the schizophrenia spectrum and schizo-affective subgroups were, respectively, 13.6 and 13. A Polish group examined schizophrenia patients at 4 time points during their 11-year follow-up period. 25 This enabled them to study TA B L E 1 (Continued) the course of illness during the follow-up period and to classify their sample into 3 subgroups: stable remission (N = 11), unstable remission (N = 37) and non-remission (N = 16). Definition of remission used the standard criteria, 26 and all 11 patients in the stable remission group were remitted at the follow-up end-point; hence, the 17.2% (11/64) of patients are listed as remitted in our Table 1 . It is important to know that in that subgroup, the actual (total) PANSS score at the end-point was 42.8, which was an increase in comparison with the baseline of 40.5. Both numbers indicate low levels of symptomatology. The baseline scores in the other 2 subgroups are substantially higher, but the PANSS scores increased in all 3 groups.
Measures of social functioning and quality of life showed very little change during the follow-up period.
A total of 373 FEP patients were followed up for 20 years in a study conducted in Suffolk county (New York). 27 Follow-ups were conducted at 6 months, 2 years, 4 years, 10 years and 20 years. A subset (N = 175) of this group was diagnosed with schizophrenia spectrum disorders, and this subset is described in our The outcome in the schizophrenia subset was generally poor. An Italian study has demonstrated that the patients who showed low severity of core schizophrenia symptoms (particularly negative symptoms) at baseline were more likely to be in symptomatic remission at follow-up 16 years later. 28 Most of the patients who were in remission at follow-up had fulfilled the standard remission criteria 26 at baseline. Thus, similar to Jaracz et al 25 , the Italian study detected a subgroup of patients who had low level of symptoms at baseline (meeting remission criteria) and at outcome.
A study of the effect of financial strain and social network on the outcome of first episode of psychosis was conducted in Sweden. 29 The patients were divided into recovered (N = 52) and non-recovered (N = 19) according to their 5-year outcome. The "non-recovered" patients (non-recovery was also referred to as "poor outcome") had a GAF score <60 for at least the past 6 months and needed continuous antipsychotic medication. The "recovered" patients ("good outcome") had stable GAF ≥60 for at least 6 months and were "living a normal life" with or without antipsychotic medication.
Each patient was matched on age and gender with 4 control subjects (N = 284) from a population-based study. All participants answered a questionnaire including social network, financial strain and mental health. Regression analyses showed that both financial strain and social network had unique contributions to outcome.
Financial strain and inadequate social network were associated with poor outcome. Social networks in patients (both recovered and nonrecovered) were impaired in comparison with the population controls.
The Northern Finland Birth Cohort report detected 175 eligible patients with schizophrenia spectrum disorders, 69 (39.4%) of whom participated in the study. Data including at least 10 years of follow-up were obtained in 53 patients, 47 of whom were diagnosed with schizophrenia using the DSM-IV criteria. 30 The average follow-up duration was 18.6 years; follow-up results at 10 years are reported. At that point, 30% of the patients were in remission. Furthermore, lack of treatment was associated with higher mortality.
Measures
Compared with treated patients, those who were never treated were significantly older had significantly fewer family members, had higher rates of homelessness, being unmarried, living alone, being without a caregiver and poor family attitudes, including patient maltreatment. Ran's group has published a series of other papers dealing with various aspects of this 14-year follow-up.
31-36
An Indian prospective study with a 10-year follow-up focused on predictors of long-term outcome. 37 The Clinical Global Impression
Scale-Improvement (CGIS-I) 38 was used to assess overall clinical change. The patients showed significant improvements on CGIs-I, PANSS, GAF and some, but not all, other specific indicators of functioning. Social functioning and ability to work have not significantly improved.
This study is exceptional in that it systematically examined the patients' aggressive behaviour. Aggression was "measured on a scale of 1-5." For analyses, the item was dichotomised, with aggression rated as present if the score >2. The baseline score >2 was observed in 63.4% of the patients, which decreased to 38.6% at follow-up.
Aggression at baseline was an independent predictor of poor outcome.
A Scandinavian study concentrated on the effects of substance use comorbidity on psychosis outcome at 10-year follow-up. 39 This was a part of a larger project (Early Treatment and Intervention in First-Episode Psychosis (TIPS)) study that also generated the paper to participate in an intensive early intervention programme (OPUS trial). They were divided into 4 outcome groups: remitted on medication, remitted off medication, non-remitted on medication and non-remitted off medication. 40 To be classified as "on medication," the patient had to use oral medication "on a daily basis" or to be on a depot antipsychotic. Patients who were prescribed daily medication but were only partially compliant were classified as "on medication" (Carsten Hjorthoj, personal communication, 11/6/17).
Patients who did not take their prescribed antipsychotic at all were considered non-compliance and classified as "off medication." The principal finding was that that 30% of the patients were remitted and "off medication" at the 10-year follow-up. However, the authors noted a selective attrition bias: patients who attended the 10-year follow-up had a significantly higher GAF baseline score than those who did not.
A study by Wunderink et al started with a 2-year prospective randomised trial that examined the effects of guided discontinuation or dose reduction in medication treatment in comparison with continued maintenance in 128 Dutch patients with first-episode psychosis (58 diagnosed with schizophrenia, 70 with other non-affective psychosis). 1 Discontinuation was associated with more relapses than maintenance. After the end of this randomised trial, the patients were followed up in an observational study for another 5 years. 41 Thus, the final outcome was assessed 7 years after the beginning of the randomised trial. Medication data were obtained for the last 2 years. It turned out that the patients assigned to the discontinuation arm in the randomised trial (the first 2 years) were prescribed lower doses (mean dose in haloperidol equivalent 2.20 mg/d) than those in the maintenance arm (3.60 mg/d) during the last 2 years of the 7-year study.
At the 7-year follow-up, symptoms were assessed with the PANSS, and social functioning with the Groningen Scale. 42 The recovery rate of the patients who had been assigned to the discontinuation group in the randomised trial was 40.4%, compared with 17.6%
in the maintenance group (29.1% in the entire sample). Functional remission was numerically more prevalent in the discontinuation than in the maintenance group. Symptomatic and functional remission was seen, respectively, in 68.0% and 33.0% of the entire sample.
Separate results for outcome in schizophrenia and other psychoses were not provided, but diagnosis had no significant effect on outcome in the analyses. 41 In summary, the 14 studies of long-term outcome of schizophrenia vary in their methods. They differ in diagnostic procedures and definitions, duration of their follow-up, measures of symptomatic and functional change, quality of mental healthcare and many other aspects. Nevertheless, we can offer a brief summary.
First, there is increasing evidence that a proportion (perhaps 20%) of schizophrenia and schizophrenia spectrum patients may have good long-term outcomes without antipsychotic treatment continued beyond 5 years, and that patients who are treated with lower doses may have better outcomes than those with higher doses.
Second, the average proportion of patients with symptomatic remission at follow-up ranged from 16.4% in never-treated patients 18 to 34.1% of treated patients in the same study 18 to 37.5% in patients who were systematically treated with monitored adherence to antipsychotics. 28 Rates of remission were lower in patients diagnosed with schizophrenia than in those with schizophrenia spectrum or non-affective psychosis.
Third, detecting and treating comorbid substance use as early as possible is important since early substance use termination predicts better long-term outcome.
Fourth, early detection and intensive treatment of the first episode as well as the quality of continued mental healthcare appear to influence long-term outcomes.
| Predictors of long-term outcome
Some patients with schizophrenia do not need very long-term pharmacologic treatment, but currently, the only way to identify them is to observe them during and after guided discontinuation Unlike many other predictors of outcome, duration of untreated psychosis (DUP) is potentially malleable. Shorter DUP predicted better outcomes of schizophrenia in a German 15-year prospective study. 43 The subjects were 58 schizophrenia patients diagnosed with DSM-3. Similar observations were reported by others. 25, 40, 41 In a 12-year follow-up study, the relationship between DUP and outcome was assessed in a sample of 171 patients, 86 of whom were diagnosed with schizophrenia or schizo-affective disorder. 20 Separate analysis for this schizophrenia subset show gradual increase in positive and negative symptoms and deterioration of functionality as the DUP gradually increased from <1 month to >1 year.
When all predictors were entered into a regression model for functional outcome, DUP explained 10.4% of outcome variance-a statistically significant proportion (P < .001).
A 10-year follow-up study of a cohort of 109 English patients with first-episode psychosis focused on outcome predictors. 44 Schizophrenia, schizophreniform disorder or schizo-affective disorder were diagnosed in 79 patients, and 49 of these patients were used in separate logistic regression analyses run for this subset.
The results showed that functional outcome was predicted by poor premorbid adjustment (assessed with the Premorbid Adjustment Scale). 45 Service dependency (admissions, independent living) was predicted by the presence of neurological soft signs, and symptoms were predicted by both soft signs and DUP.
The effects of DUP and other variables on outcome were examined by Friis et al 46 in a study that was a part of the Scandinavian The onset of schizophrenia is earlier in males, and early onset is associated with worse prognosis.
The mode of onset of schizophrenia has a prognostic significance.
Cases with acute onset have a better prognosis than those where the onset is insidious. Acute onset is variously defined as an emergence of psychotic symptoms over a period lasting for a day or up to 1 month. 10 In insidious onset, symptoms develop more gradually, over a longer period than 1 month. It is possible that the reason why insidious onset is associated with worse prognosis is that it leads to a longer DUP. The finding that higher levels of negative symptoms at baseline predict poorer outcome 37 perhaps implies insidious onset.
Other predictors of worse prognosis include earlier age of onset, higher levels of aggression 37 and worse cognitive functioning.
A meta-analysis indicated that long DUP correlated significantly with poor general symptomatic outcome and poor social functioning and global outcome. 48 However, long DUP was not associated with employment, quality of life or hospital treatment.
Overall, it is clear that longer DUP is generally associated with worse outcomes, but the relationship is complicated and DUP alone is not a clinically useful predictor. Its principal clinical importance is that it provides motivation for early detection and treatment of psychosis, particularly schizophrenia. The other predictors such as gender, premorbid adjustment and mode and age of onset are heuristically interesting, but their prognostic power does not appear to be superior to DUP. The field is waiting for the development of biological predictors that might offer more power.
| D ISCUSS I ON
The present finding that some schizophrenia and schizophrenia spectrum patients can achieve good long-term outcomes without continued maintenance antipsychotics was partly based on reports by Harrow et al 17 and by Wils et al 40 The Harrow et al report 17 showed that the patients who were medication off had consistently better employment rates (>70%) than those on it (25%-35%), and one of the explanations offered by the authors for the poor work functioning in the medicated patients was a "progressive loss of antipsychotic efficacy after the first 2 years." However, this result might, perhaps, reflect a potential loss of treatment adherence in the medicated subset; no systematic and rigorous monitoring of adherence was apparently in place.
Several explanations for the good work functioning in unmed- The Harrow and Wils results may be compared with the findings of a large international long-term study of recovery from psychosis. 10 Patients diagnosed with schizophrenia showed recovery rates of 37.8% if they were treated with medication in the past 2 years, and 16% if they were not. The analogous numbers for other psychoses were 54.8% and 35.8%.
A study of DSM-III schizophrenia long-term patients hospitalised in a private US hospital revealed that 23 of 163 (14%) showed good outcomes without antipsychotic medication. 9 Taking together all these data, we estimate that approximately 20% of schizophrenia patients do not need continued long-term maintenance antipsychotic treatment to achieve good outcomes in terms of symptomatic and/or functional remission. This estimate is in line with that of Goff et al 13 and with older literature. 49, 50 Our present data suggest that this proportion may be higher than 20% in schizophrenia spectrum patients. This may be true, and there are some indications that minor improvements in care could have resulted in better outcomes. Table   S4 shows that, in the schizophrenia patients, the frequency of medication visits (but not psychotherapy visits) was significantly associated with reductions of psychotic symptoms, disorganisation and excitement. It is conceivable that the medication visits resulted in improved adherence, which led to symptom reduction. Since psychotherapy visits had no effect on symptoms, the symptomatic im- Mattsson et al study 29 is unique in that it examines the detrimental role of financial strain and social networks in the recovery from schizophrenia and related disorders. These factors had independent contributions to the outcome. Thus, first-episode patients might benefit from interventions that reduce financial strain. Such interventions could facilitate cultural and social activities, which in turn might lead to enrichment of social networks.
Moilanen et al studied relationships between antipsychotic treatment and outcome. 30 Low antipsychotic doses and proportion of use, as well as having no drug-free periods, were the treatment features associated with better outcomes. High doses and proportions of use, as well as polypharmacy, were associated with poorer outcomes. Moilanen's insightful interpretation of these associations
is that "subjects with more severe illness or treatment-resistant schizophrenia may receive higher doses of antipsychotic medication, making higher doses a marker of a more serious illness rather than a cause of decline" (p.13). Interestingly, these authors did not make the analogous interpretation for subjects with less severe illness. Such subjects may receive lower doses of antipsychotic medication, making lower doses a marker of a less serious illness rather than a cause of improvement. Thus, confounding by indication may have affected the relationship between dose and outcome. 51 Theoretically, such issues could be addressed by randomised controlled trials, but these would be extremely difficult if not impossible to run for 10 years (like the Moilanen study). However, some relevant information could be collected within the constraints of future observational studies. With increased frequency of intermediate observations within a 10-year follow-up, one could examine the temporal relationship between the changes in behaviour of the patient and changes of prescriptions. Importantly, one could also obtain data on adherence.
Preliminary data addressing the reasons for prescribing high doses have been published. 52 Chart reviews revealed that the highdose patients had a persistent course of illness with severe symptoms. The high doses were continued without evidence that they were effective. These observations may be seen as support for the notion that high doses are a marker of more serious illness.
Ran's large epidemiological sample of treated and never-treated schizophrenia patients is an important asset. 18 The difference in remission rates at end-point (16.4% of never treated, but 34.1% of treated patients) could be seen as support for continued maintenance treatment. Furthermore, increased mortality in the never-treated patients is consistent with an observational study by Tiihonen et al that demonstrated lower mortality in schizophrenia patients who were exposed to antipsychotics than in the non-exposed. 53 However, some of the environmental factors such as homelessness, poor family relationships and maltreatment (victimisation) may have contributed to the poor outcomes in the never-treated group; Ran's data and analyses, thus, do not prove that lack of treatment was a statistically independent predictor of poor outcomes. In this context, we note that patients in a 1949 Czech cohort who had never received antipsychotics had markedly longer durations of hospitalisation than patients from subsequent cohorts who did receive them. 54 The sample reported by the Indian authors 37 provides an important insight into schizophrenia outcome in a culture that is different from that prevailing in the environment of most other studies.
Furthermore, the study showed the importance of social parameters in the complete assessment of the patients' life. The assessment of aggression in this study is unique and the results are striking, with 63% of the patients showing more than minimal aggression at baseline. Furthermore, aggression at baseline was an independent predictor of poor outcome. These findings should inspire other researchers to include one of the standard measures of aggression into their baseline and follow-up assessments.
Compelling data showing deleterious effect of comorbid substance use on long-term outcome were presented by Weibell et al. 39 The significance of these data should be seen in the context of recent large epidemiological investigations reporting comorbid use of recreational drugs in 35% of persons diagnosed with schizophrenia and an odds ratio of 4.62 in comparison with general population. 55 Future analyses of long-term outcome of schizophrenia should account for substance use since it is an important source of variance.
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VOLAVKA And VEVERA
The results of Wunderink et al 1, 41 are difficult to interpret. The project is a sequence of a randomised trial followed by an observational study, with the original assignment in the randomised phase appearing to influence the dosing in the subsequent observational phase; the patients who had been randomly assigned to discontinuation were later prescribed lower doses in the observational study (average 2.3 mg haloperidol equivalent) than those who had been assigned to maintenance (3.6 mg). Thus, the second phase of the project can be seen as a mixture of randomised and observational study. This would seem to make the second phase of the project less open to bias than regular observational studies. On the other hand, the possibility of bias was increased since raters
were not blinded to the patients' medication during the project. Murray et al interpreted the Wunderink results as a loss of effectiveness of antipsychotics, speculating that dopamine receptor supersensitivity could be an underlying mechanism. 12 Animal studies supporting this possibility are available. When rats were treated with haloperidol or olanzapine, these drugs initially exerted antipsychoticlike effects (suppression of amphetamine-induced locomotion and conditioned avoidance responding). 58 However, with continued treatment, these antipsychotics progressively lost their efficacy. The loss of efficacy was linked to an increase in D2 receptor number and sensitivity.
In humans, neostriatal dopamine receptor supersensitivity has been linked to the development of tardive dyskinesia after longterm treatment with first generation antipsychotics. It has been suggested that antipsychotic exposure also elicits dopaminergic supersensitivity in the mesolimbic area, and this may lead to the development of tolerance to antipsychotic effects of the drugs, as well as to supersensitivity psychosis, particularly upon withdrawal of the treatment. 59 Tardive dyskinesia appears or gets worse concomitantly with the supersensitivity psychosis. Worsening of psychotic symptoms was temporally associated with the onset of tardive dyskinesia in a large sample of schizophrenia patients 60 Additional data on supersensitivity can be found elsewhere. 12 Whatever mechanism may be involved, the Wunderink results were obtained in a relatively small number of subjects and require replication. In the meantime, they elicited considerable debate. 13, 14 Overall, the results show considerable variability. This could be explained in part by differences in diagnostic criteria across the studies we reviewed (Table 1) . Various editions of the DSM were used in 11 studies, 2 studies used the ICD-10, and one study specified no diagnostic criteria. The studies share, to varying extent, other limitations that restrict their generalisability. There is the unavoidable patient selection bias due to the need for ability and willingness to provide informed consent. Other reasons for non-participation of eligible patients exist, and these are not always adequately explained.
Furthermore, the weighted mean of the participant attrition rates during follow-up was 36.5%, the range was 17.1%-59.4%. The reasons for attrition remain largely unexplained, and their effect on the results is uncertain. These problems make it necessary to view these results with caution.
| CON CLUS ION
A proportion of schizophrenia patients, perhaps 20%, do not need maintenance treatment with antipsychotics beyond 5 years after the first episode to achieve recovery. Our present data suggest that this proportion may be higher than 20% in schizophrenia spectrum patients. Emerging research seems to suggest that antipsychotics may at least partially lose their beneficial effects after the first 3 or 4 years of treatment, but other explanations, such as natural course of schizophrenia, may also explain these data.
Furthermore, although dose reduction after 4 years seems to be associated with better outcomes, causality between these variables has not been established.
Discontinuation of antipsychotic treatment works well for the patients who do not need it (perhaps 20%), but not for the 80% who do. Unfortunately, we are unable to predict which individuals belong to which of these 2 groups. In general, discontinuation of antipsychotic treatment increases the risk of relapse.
Given that, the clinician should develop a collaborative relationship with the patient in determining the lowest effective dose. Careful evaluation of risks and benefits is necessary in each individual case.
Particular caution must be exercised if the patient has a history of violence or suicidal attempt. "The use of low doses of medication or of medication discontinuation may have long-term benefit for some patients, but a weighing of a relative risk of relapse compared with exposure to higher doses of medication remains to be clarified."
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